Navigation Links
Weill Cornell presents updated results from Phase 3 trial of IVIG for Alzheimer's disease
Date:7/16/2013

NEW YORK (July 16, 2013) -- Weill Cornell Medical College neurologist Dr. Norman Relkin reported new findings today from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in Boston, Mass. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.

IVIG is a mixture of antibodies derived from the blood of healthy donors. Given its ability to control infection and inflammation, IVIG has been used to treat disease for more than 30 years. It has been approved for use in treating several disorders, ranging from pediatric immune disorders to a blood cancer and Kawasaki disease, but is not approved for Alzheimer's disease.

The Gammaglobulin Alzheimer's Partnership (GAP) Study was a Phase 3, randomized, double-blind, placebo-controlled clinical trial in 390 people with mild to moderate Alzheimer's disease, conducted at 45 centers in the U.S. and Canada. Two different doses of IVIG were tested versus placebo as add-ons to approved Alzheimer's medications. The drug was administered every two weeks for 18 months. Primary study endpoints were changes on two well-established tests of cognition and daily functioning -- the ADAS-Cog and ADCS-ADL.

In a topline announcement in May, the GAP researchers reported negative results on the GAP study's primary outcomes -- the ADAS-Cog and ADCS-ADL. At the same time, preliminary observations were reported on favorable changes on another cognitive test, the Modified Minimental State Examination (3MS) in two subgroups: people with Alzheimer's who carried the APOE-e4 Alzheimer's risk gene, and those who were moderately impaired. The study was not powered to show statistical significance in these pre-planned
'/>"/>

Contact: John Rodgers
pr@med.cornell.edu
646-317-7401
Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
2. Weill Cornell awarded $1.8 million for translational blood cancer research
3. Weill Cornell receives $1.5 million in Grand Challenges Explorations grants
4. New Institute for Precision Medicine created at Weill Cornell and NewYork-Presbyterian
5. Weill Cornell Medical School Teams with MediGait to Get the Elderly, Sufferers of Parkinson’s and Multiple Sclerosis “Back on their Feet”
6. Dr. Augustine M. K. Choi Appointed Chairman of Medicine at Weill Cornell Medical College and Physician-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center
7. Second annual Brain Tumor Biotech Summit 2013 at Weill Cornell
8. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
9. Cornell Dubilier Launches New Website with Advance Capacitor Search
10. Cornell Dubilier Announces Long-Life Ultracapacitors
11. CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... The Williams Rejuva Center excited to ... patient’s unique treatment regime. Using the Vectra 3D ... trouble areas can be quickly created. The evaluation ... , Vectra 3D is a cutting-edge computer imaging system. ... a quick ‘snapshot’ of the skin to determine the ...
(Date:7/11/2014)... 11, 2014 Even the hot Texas sun ... Elementary School . The school had previously invested ... equipment from APCPLAY, but recently asked for an innovative ... , Godley Elementary School chose a Rectangular Shade from ... for children on their playground. The shade measures 24’W ...
(Date:7/11/2014)... July 11, 2014 Shu Cosmetic ... perineplasty for each qualifying patient undergoing a ... been performing laser vaginal rejuvenation, an advanced type ... The LVR procedure decreases the internal and external ... muscle tone, strength, and control, resulting in enhanced ...
(Date:7/11/2014)... ASHBURN PSYCHOLOGICAL AND PSYCHIATRIC SERVICES , On July 1st, Senate ... disability or autism to have a special code placed on ... law enforcement or first responders that they are dealing with ... a central Virginia mother, Ms. Pam Mines, who wanted to ... JP. During a news conference after the law passed, ...
(Date:7/10/2014)... (PRWEB) July 11, 2014 Karen Middleton, ... President and CEO of Planned Parenthood of the Rocky ... Senator Mark Udall and Representative Diana DeGette were in ... Court’s Hobby Lobby decision and keeping bosses out of ... representatives listened to the president today in Denver addressing ...
Breaking Medicine News(10 mins):Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 3Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2
... ... for the Apple® iPhone. Module is the world’s first all-purpose iPhone case to ... ... February 24, 2010 -- Dacha Works LLC , the mobile computing accessories company, ...
... ... Company’s Future Growth , ... (PRWEB) March 17, 2010 -- Group Logic, a leading provider of desktop ... the company’s new chief executive officer (CEO). As a software industry veteran, Broderick ...
... Highly educated white men most likely to be tipplers, study ... to two-thirds (61 percent) of American adults consider themselves drinkers, ... likely to drink alcohol than women, and people with more ... of U.S. residents say they,ve abstained their whole lives. ...
... ... pharmacists with valuable information on topics such as operations management, economic analysis, reimbursement ... human resource strategies – vital competencies for pharmacy leaders and managers. , ... Sudbury, MA ...
... ... and high rates of asthma in Washington, DC. , ... Washington, DC (Vocus) March 17, 2010 -- Researchers ... asthma in metropolitan Washington, DC, are significantly more likely to have low levels of ...
... Worldwide Edition for his outstanding contributions and achievements in the field of healthcare. , ... , ... ... , ...
Cached Medicine News:Health News:Dacha Works Introduces Module- A Revolution In iPhone Case Design 2Health News:Group Logic, Inc. Appoints New CEO 2Health News:Group Logic, Inc. Appoints New CEO 3Health News:6 Out of 10 American Adults Drink 2Health News:New Book Reviews Core Competencies for Pharmacy Leaders 2Health News:New Book Reviews Core Competencies for Pharmacy Leaders 3Health News:New Book Reviews Core Competencies for Pharmacy Leaders 4Health News:Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids 2Health News:Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids 3Health News:Dr. Mark Russell Recognized By Strathmore's Who's Who Worldwide Publication 2
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: